ethyl vinyl sulfate | 90587-34-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: ethyl vinyl sulfate
• 英文别名: Ethenyl ethyl sulfate；ethenyl ethyl sulfate
• CAS: 90587-34-1
• 化学式: C₄H₈O₄S
• 分子量: 152.171
• InChiKey: TUXCDMXMEJWDQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-butyl-8-(piperidin-4-yloxy)quinoline 、 ethyl vinyl sulfate 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 以70%的产率得到6-Butyl-8-[1-(2-ethylsulfonylethyl)piperidin-4-yl]oxyquinoline
  参考文献：
  名称：

  Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis

  摘要：

  A series of potent, selective and long-acting quinoline-based sulfonamide human H-1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H-1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine. (C) 2017 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2017.09.020

文献信息

• Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis
  作者：Panayiotis A. Procopiou、Alison J. Ford、Paul M. Gore、Ashley P. Hancock、Simon T. Hodgson、Duncan S. Holmes、Brian E. Looker、Sadie Vile、Kenneth L. Clark、Ken A. Saunders、Robert J. Slack、Clarissa J. Watts

  DOI：10.1016/j.bmcl.2017.09.020

  日期：2017.11

  A series of potent, selective and long-acting quinoline-based sulfonamide human H-1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H-1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine. (C) 2017 Published by Elsevier Ltd.